US Patent

US8617595 — Galenic formulations of organic compounds

Formulation · Assigned to Novartis AG · Expires 2026-02-19 · 0y expired

Vulnerability score 50/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a solid oral dosage form containing aliskiren or a salt thereof, with the active ingredient making up more than 46% of the dosage form's weight.

USPTO Abstract

The present invention relates to a solid oral dosage form comprising a therapeutically effective amount of aliskiren or a pharmaceutically acceptable salt thereof, and wherein the active ingredient is present in an amount of more than 46% by weight based on the total weight of the oral dosage form.

Drugs covered by this patent

Patent Metadata

Patent number: US8617595
Jurisdiction: US
Classification: Formulation
Expires: 2026-02-19
Drug substance claim: No
Drug product claim: Yes
Assignee: Novartis AG
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.